



NAVANA PHARMA

NAVANA PHARMACEUTICALS PLC.

Corporate Office:

99 Gulshan Avenue, Rupayan Golden Age, 6th Floor, Plot-6, Block-CWN (C), Dhaka-1212.

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC and stakeholders that the Board of Directors of the company in its 65th meeting held on January 28, 2026 ended at 4.00 p.m. has considered and approved, among others, the Un-Audited Financial Statements for the Second quarter (Q2) period ended on December 31, 2025 and took the following Price Sensitive Decision: -

Comparative Statement on Un-Audited Financial Statement for the Second quarter (Q2, FY-2025-2026) period ended on December 31, 2025:

Sl. No	Particulars	01.07.2025-31.12.2025	01.07.2024-31.12.2024	01.10.2025-31.12.2025	01.10.2024-31.12.2024
I	Net Profit After Tax	362,669,843	241,444,123	179,035,804	107,694,911
II	Earnings Per Share (EPS)	3.38	2.25	1.67	1.00
		3.35 (Diluted)	N/A	1.65 (Diluted)	N/A
III	Net Operating Cash Flow Per Share (NOCFPS)	8.11	3.16	N/A	N/A
		As on 31.12.2025	As on 30.06.2025		
IV	Net Asset Value (NAV)	5,190,649,929	4,864,919,141	N/A	N/A
V	Net Asset Value Per Share	48.32	45.29	N/A	N/A

Notes:

- ❖ Reasons of significant deviation in Earning per Share (EPS) & Net Operating Cash Flow Per Share (NOCFPS) between the periods:
 - ▶ **EPS:** Net Profit after Tax has increased significantly due to the increment of Net Sales & Gross Profit as well as reduction of finance cost, as a result half yearly Earnings per Share (EPS) increased by 50.22% from the previous year.
 - ▶ **NOCFPS:** Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 8.11 from Tk. 3.16, because of cash received from the customers was higher than the cash payment to the vendors & others in the reporting period.
- ❖ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-Audited Financial Statement for the Second quarter (Q2) period ended on December 31, 2025 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

By order of the Board

Sd/-

Dr. Sayeed Ahmed

Managing Director

Dated: January 28, 2026